Immunotherapy combo tested against untreatable liver cancer

NCT ID NCT07679061

Recruiting now Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study observes how a combination of two immunotherapy drugs, nivolumab and ipilimumab, works for people with advanced liver cancer that cannot be removed by surgery. It follows adults receiving this treatment as part of their routine medical care in Japan to understand its safety and effectiveness in real-world practice. The main focus is on tracking immune-related liver side effects and how well the drugs control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab plus ipilimumab
What this could lead to: If successful, this could confirm that combining these two immunotherapy drugs is a safe and effective standard treatment for advanced liver cancer that cannot be surgically removed.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. The combination can cause immune-related side effects, including liver injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNRESECTABLE HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Mebix. Inc
RECRUITING

Minato-ku, Tokyo, 1050001, Japan
National Cancer Center Hospital East
RECRUITING

Chiba, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.